NEW YORK, Nov. 3, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cempra Inc. ("Cempra" or the "Company") (NASDAQ: CEMP). Investors who purchased or otherwise acquired Cempra shares between August 1, 2016 and November 1, 2016 are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at email@example.com or 212-697-6484. The investigation concerns whether Cempra and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On November 2, 2016, the U.S. Food and Drug Administration reported its preliminary review of Cempra's drug, solithromycin, to treat community-acquired bacterial pneumonia and specified a significant safety signal for hepatotoxicity. Following this news, CEMP stock dropped $9.71 per share or over 58% to $6.95 on November 2, 2016. If you are aware of any facts relating to this investigation, or purchased shares of Cempra, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/cemp. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.